Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index.

Targeting Histone Deacetylase 8 as a Therapeutic Approach to Cancer and Neurodegenerative Diseases

Open access

Abstract

Histone deacetylase 8 (HDAC8), a unique class I zinc-dependent HDAC, is an emerging target in cancer and other diseases. Its substrate repertoire extends beyond histones to many nonhistone proteins. Besides being a deacetylase, HDAC8 also mediates signaling via scaffolding functions. Aberrant expression or deregulated interactions with transcription factors are critical in HDAC8-dependent cancers. Many potent HDAC8-selective inhibitors with cellular activity and anticancer effects have been reported. We present HDAC8 as a druggable target and discuss inhibitors of different chemical scaffolds with cellular effects. Furthermore, we review HDAC8 activators that revert activity of mutant enzymes. Isotype-selective HDAC8 targeting in patients with HDAC8-relevant cancers is challenging, however, is promising to avoid adverse side effects as observed with pan-HDAC inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4155/fmc-2016-0117

Cites

127 of 127 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Histone deacetylase 8 crystal structures. Similarities (A, B) and differences (C-E) between HDAC8 and other histone deacetylases. (A & B) Superimposed all currently available 56 x-ray structures of human and parasitic HDACs (hHDAC1, hHDAC2, hHDAC3, hHDAC8, smHDAC8, hHDAC4 and hHDAC7). The zinc ion (orange ball) and the ligand (SAHA, gray sticks) are shown for hHDAC8 PDB ID 1T69 to define the binding pocket. (A) Common catalytic domain in all HDACs, built by conserved β -sheet (yellow ribbons) surrounded by α -helices (red ribbons) and flexible loops. Loops (or their parts), forming the binding pocket, are colored (L1 - cyan, L2 - turquoise, L3 - blue, L4 - lime, L5 - dark green, L6 - magenta, L7 - deep purple) and the others are white. (B) Conserved binding pocket residues (dark yellow sticks) are adopting similar side chain conformations in different HDACs. The numbers of residues are given only for hHDAC8 for clarity. The loops, bearing the conserved residues are shown as ribbons and colored in the same way as in (A) : L3 - blue, L4 - lime, L5 - dark green and L6 - magenta. (C-E) Differences between HDAC8 (cyan residues, L3 and surface of the binding pocket, turquoise ligand) and other HDAC isotypes (white residues, L3 and surface of the binding pocket, gray ligand). Zinc ions are shown as orange ball. Only residues, changing the binding pocket shape dramatically are shown for clarity. (C) Comparison of hHDAC8 (PDB ID 3SFH) and hHDAC7 (PDB ID 3ZNS) - foot pocket in hHDAC8 is opened by the movement of the gatekeeper residue W141, while in hHDAC4 it is closed because of the different orientation of the L3. (D) Comparison of hHDAC8 (PDB ID 3SFH) and hHDAC2 (PDB ID 4LY1) - foot pocket is opened in both isotypes and the orientation of L3 is the same, but the gatekeeper residue in hHDAC8 (W141) is bigger than in hHDAC2 (L144), which restricts the space in this area. (E) Comparison of hHDAC8 (PDB ID 2V5X) and hHDAC2 (PDB ID 4LXZ) - side pocket is observed in hHDAC8, but is closed in hHDAC2, which is caused by a closer proximity of the gatekeeper residues in hHDAC2 (F155 and L276) than in hHDAC8 (F152 and M274). HDAC: Histone deacetylase; SAHA: Suberoylanilide hydroxamic acid.
Figure 1 Histone deacetylase 8 crystal structures. Similarities (A, B) and differences (C-E) between HDAC8 and other histone deacetylases. (A & B) Superimposed all currently available 56 x-ray structures of human and parasitic HDACs (hHDAC1, hHDAC2, hHDAC3, hHDAC8, smHDAC8, hHDAC4 and hHDAC7). The zinc ion (orange ball) and the ligand (SAHA, gray sticks) are shown for hHDAC8 PDB ID 1T69 to define the binding pocket. (A) Common catalytic domain in all HDACs, built by conserved β -sheet (yellow ribbons) surrounded by α -helices (red ribbons) and flexible loops. Loops (or their parts), forming the binding pocket, are colored (L1 - cyan, L2 - turquoise, L3 - blue, L4 - lime, L5 - dark green, L6 - magenta, L7 - deep purple) and the others are white. (B) Conserved binding pocket residues (dark yellow sticks) are adopting similar side chain conformations in different HDACs. The numbers of residues are given only for hHDAC8 for clarity. The loops, bearing the conserved residues are shown as ribbons and colored in the same way as in (A) : L3 - blue, L4 - lime, L5 - dark green and L6 - magenta. (C-E) Differences between HDAC8 (cyan residues, L3 and surface of the binding pocket, turquoise ligand) and other HDAC isotypes (white residues, L3 and surface of the binding pocket, gray ligand). Zinc ions are shown as orange ball. Only residues, changing the binding pocket shape dramatically are shown for clarity. (C) Comparison of hHDAC8 (PDB ID 3SFH) and hHDAC7 (PDB ID 3ZNS) - foot pocket in hHDAC8 is opened by the movement of the gatekeeper residue W141, while in hHDAC4 it is closed because of the different orientation of the L3. (D) Comparison of hHDAC8 (PDB ID 3SFH) and hHDAC2 (PDB ID 4LY1) - foot pocket is opened in both isotypes and the orientation of L3 is the same, but the gatekeeper residue in hHDAC8 (W141) is bigger than in hHDAC2 (L144), which restricts the space in this area. (E) Comparison of hHDAC8 (PDB ID 2V5X) and hHDAC2 (PDB ID 4LXZ) - side pocket is observed in hHDAC8, but is closed in hHDAC2, which is caused by a closer proximity of the gatekeeper residues in hHDAC2 (F155 and L276) than in hHDAC8 (F152 and M274). HDAC: Histone deacetylase; SAHA: Suberoylanilide hydroxamic acid.CC-BY-NC-ND · From the PDF
Figure 2 Histone deacetylase 8 expression in normal and tumor cells. R2 MegaSampler [66] with HDAC8 probe 223345_at. (A) HDAC8 expression of normal B cells (N1-2, blue), leukocytes (N3, blue) and expression in AML (1-8, green) and ALL (1-5, orange). (B) Normal (blue) colon (N1) expression compared with expression in colon cancer (T Colon 1-15, red). (C) Normal neural crest (N1, blue) expression compared with expression in neuroblastoma (1-4). (D) Normal neural crest (N1, blue) expression compared with expression in neuroblastoma INSS stage 4 and stage 4s samples of the Versteeg (1), Delattre (2), Hiyama (3) and Latowska (4) cohort. ALL: Acute lymphocytic leukemia; AML: Acute myeloid leukemia; HDAC8: Histone deacetylase 8.
Figure 2 Histone deacetylase 8 expression in normal and tumor cells. R2 MegaSampler [66] with HDAC8 probe 223345_at. (A) HDAC8 expression of normal B cells (N1-2, blue), leukocytes (N3, blue) and expression in AML (1-8, green) and ALL (1-5, orange). (B) Normal (blue) colon (N1) expression compared with expression in colon cancer (T Colon 1-15, red). (C) Normal neural crest (N1, blue) expression compared with expression in neuroblastoma (1-4). (D) Normal neural crest (N1, blue) expression compared with expression in neuroblastoma INSS stage 4 and stage 4s samples of the Versteeg (1), Delattre (2), Hiyama (3) and Latowska (4) cohort. ALL: Acute lymphocytic leukemia; AML: Acute myeloid leukemia; HDAC8: Histone deacetylase 8.CC-BY-NC-ND · From the PDF
Image 3
CC-BY-NC-ND · From the PDF
Image 4
CC-BY-NC-ND · From the PDF
Image 5
CC-BY-NC-ND · From the PDF
Image 6
CC-BY-NC-ND · From the PDF
Figure 5 Crystal structure of histone deacetylase 8 in complex with an amino acid derivative (PDB ID3SFF) showing the addressing of the foot pocket.
Figure 5 Crystal structure of histone deacetylase 8 in complex with an amino acid derivative (PDB ID3SFF) showing the addressing of the foot pocket.CC-BY-NC-ND · From the PDF
Image 8
CC-BY-NC-ND · From the PDF
Image 9
CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Cited by

See all 123

Metadata

Authors
Chakrabarti, A., Melesina, J., Kolbinger, F. R., Oehme, I., Senger, J., Witt, O., Sippl, W., & Jung, M.
Affiliations
  • University of Freiburg (DE)
  • Martin Luther University Halle-Wittenberg (DE)
  • German Cancer Research Center (DE)
Venue
Future Medicinal Chemistry
Published
2016-08-30
Volume
8
Issue
13
Pages
1609-1634
ISSN
  • 1756-8919 (ISSN-L)
  • 1756-8927
OpenAlex
W2510695850
Cited by
111
References
127
Citations by year
2026: 8 · 2025: 9 · 2024: 12 · 2023: 8 · 2022: 14 · 2021: 8 · 2020: 15 · 2019: 14 · 2018: 14 · 2017: 9
FWCI
1.21
Type
journal article
Language
en
Open access
Locations
  • Future Medicinal Chemistry (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
Funders
H.W. & J Hector foundation
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
HDAC8, HDAC8 inhibitors, class I HDACs, transcription factor interaction, cancer therapy, neurodegenerative diseases
MeSH terms
Antineoplastic Agents, Histone Deacetylases, Humans, Neoplasms, Repressor Proteins, Neuroprotective Agents, Neurodegenerative Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.